Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors
The limited efficacy of ICIs in MSS mCRC remains a major challenge. The association between liver metastases and inferior outcomes supports the liver's immunosuppressive role and suggests that liver metastasis status may guide patient selection and treatment optimization.
Authors
- Nussara Pakvisal (ORCID: https://orcid.org/0000-0001-8430-6151)
- Kerry L. Reynolds (ORCID: https://orcid.org/0000-0002-7793-654X)
- Leyre Zubiri
- Bennett Adam Caughey (ORCID: https://orcid.org/0000-0002-3970-1651)
- Joie Sun
- Ben Ouyang (ORCID: https://orcid.org/0000-0003-0958-165X)
- Ryan Dp
- David Ting
- Jill N. Allen (ORCID: https://orcid.org/0000-0002-1446-2981)
- Motaz Qadan
- Bryan L. Peacker
- Kruti B. Vora
- Ryan B. Corcoran
- Aparna R. Parikh
- Elizabeth P. Walsh
- Noelia Tarazona
- Bruce Giantonio
- Aditya Pandey
- Jefferey W. Clark
- Leontios Pappas
Institutions
- Instituto de Salud Carlos III (ES)
- King Chulalongkorn Memorial Hospital (TH)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0690
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Sanofi
- Exelixis
- Incyte
- Moderna